Arginine deiminase: recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug

Appl Microbiol Biotechnol. 2016 Jun;100(11):4747-60. doi: 10.1007/s00253-016-7490-z. Epub 2016 Apr 18.

Abstract

Arginine deiminase (ADI) is an important arginine-degrading enzyme with wide applications, in particular as an anti-cancer agent for the therapy of arginine-auxotrophic tumors. In recent years, novel ADIs with excellent properties have been identified from various organisms, and crystal structures of ADI were investigated. To satisfy the requirements of potential therapeutic applications, protein engineering has been performed to improve the activity and properties of ADIs. In this mini-review, we systematically summarized the latest progress on identification and crystal structure of ADIs, and protein engineering strategies for improved enzymatic properties, such as pH optimum, K m and k cat values, and thermostability. We also outlined the PEGylation of ADI for improved circulating half-life and immunogenicity, as well as their performance in clinical trials. Finally, perspectives on extracellular secretion and property improvement of ADI were discussed.

Keywords: Anti-tumor; Arginine deiminase (ADI); Directed evolution; PEGylation; Protein engineering.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology
  • Cell Line, Tumor
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Drug Synergism
  • Humans
  • Hydrogen-Ion Concentration
  • Hydrolases / chemistry*
  • Hydrolases / pharmacology
  • Mycoplasma / classification
  • Mycoplasma / enzymology
  • Mycoplasma penetrans / enzymology
  • Neoplasms / drug therapy
  • Protein Conformation
  • Protein Engineering*
  • Pseudomonas aeruginosa / enzymology

Substances

  • Antineoplastic Agents
  • Hydrolases
  • arginine deiminase